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Gastrointestinal stromal tumor (GIST) is a refractory disease in need of novel
efficacious therapy. The aim of our study was to evaluate the effectiveness of
tumor-targeting Salmonella typhimurium A1-R (S. typhimurium A1-R) using on a.e00643
. This is an open access article under the CC BY license
y/4.0/).
2 https://doi.org/10.1016/j.heliy
2405-8440/Published by Else
(http://creativecommons.org/li
Article Nowe00643patient derived orthotopic xenograft (PDOX) model of imatinib-resistant GIST. The
GIST was obtained from a patient with regional recurrence, and implanted in the
anterior gastric wall of nude mice. The GIST PDOX mice were randomized into
3 groups of 6 mice each when the tumor volume reached 60 mm3: G1, control
group; G2, imatinib group (oral administration [p.o.], daily, for 3 weeks); G3, S.
typhimurium A1-R group (intravenous [i.v.] injection, weekly, for 3 weeks). All
mice from each group were sacrificed on day 22. Relative tumor volume was
estimated by laparotomy on day 0 and day 22. Body weight of the mouse was
evaluated 2 times per week. We found that S. typhimurium A1-R significantly
reduced tumor growth in contrast to the untreated group (P ¼ 0.001). In
addition, we found that S. typhimurium A1-R was more effective compared to
imatinib (P ¼ 0.013). Furthermore, Imatinib was not significantly effective
compared to the control group (P ¼ 0.462). These results indicate that S.
typhimurium A1-R may be new effective therapy for imatinib-resistant GIST and
therefore a good candidate for clinical development of this disease.
Keywords: Biochemistry, Cancer research, Genetics, Microbiology
1. Introduction
Gastrointestinal stromal tumor (GIST) is a rare and recalcitrant tumor and may orig-
inate from the interstitial cell of Cajal [1]. It is estimated that each year the total num-
ber of new cases of GIST in the United States will be between 4,000e6,000.
Complete tumor excision without tumor rupture is the only known curative therapy
of GIST [2]. In most cases, GIST results from a mutation in one of the two tyrosine
kinase receptors genes, c-kit (75%, exon: 9, 11, 13 and 17) or platelet-derived growth
factor receptor a (PDGFRa, 10%; exon: 12, 14 and 18) [3].
Standard known chemotherapies are not effective against GIST. Three tyrosine ki-
nase inhibitors (TKIs) with c-kit inhibitory activity have been approved for the treat-
ment of GIST (imatinib, sunitinib, and regorafenib). Imatinib, a 2-phenyl amino
pyrimidine derivative, is an inhibitor of several tyrosine kinase enzymes [4, 5],
and first-line therapy for GIST [5]. Imatinib was first developed as a treatment for
chronic myeloid leukemia (CML) by inhibiting the intracellular tyrosine kinase
termed the Abelson murine leukemia viral oncogene homolog (ABL) and the kinase
breakpoint cluster region protein (BCR)-ABL fusion protein [6, 7]. Imatinib inhibits
the downstream signalling cascade, which regulates cell proliferation by interrupting
the transfer of phosphate groups from adenosine triphosphate (ATP) to tyrosine res-
idues of specific protein [7, 8]. Imatinib has been approved by the US Food and Drug
Administration (FDA), for the GIST iradication [9, 10]. Neoadjuvant chemotherapy
using imatinib is being utilized for GIST with a c-kit mutation [11]. Further, it has
been demonstrated that imatinib activated CD8(þ) T cells and induced regulatoryon.2018.e00643
vier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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Article Nowe00643T cell (T(reg) cell) apoptosis within the tumor by reducing tumor-cell expression of
the immunosuppressive enzyme indoleamine 2,3-dioxygenase (Ido) [12]. Although
imatinib improves the prognosis of patients with advanced GIST [9], approximately
50% of patients develop tumor recurrence within 2 years, due to secondary mutations
in c-kit at exons 13, 14, 16, 17 or 18 [5].
Sunitinib, a multi-tyrosine kinase inhibitor, has been considered second-line therapy
for GIST, is effective against tumors with c-kit exon 9, 13 or 14 mutations [13]. Re-
gorafenib, another tyrosine kinase inhibitor, was approved by the FDA as a third-line
therapy for advanced GIST [14], is effective against tumors with c-kit exon 16, 17 or
18 mutations [15, 16, 17, 18, 19, 20]. Clinical trials of other drugs targeting c-kit and
PFGFRa are currently ongoing [21, 22, 23]. However, all these inhibitors have
limited clinical efficacy. Therefore, new effective therapy is required to improve
the prognosis of GIST. To accomplish this goal of precision therapy, individualized
treatment of cancer patients, we have established the patient-derived orthotopic
xenograft (PDOX) nude mouse model [24].
Salmonella typhimurium A1-R (S. typhimurium A1-R) is a facultative anaerobe,
which was developed in our laboratory. S. typhimuriumA1-R can grow and replicate
in viable as well as necrotic areas of tumors [25]. S. typhimurium A1-R is auxotro-
phic (leu/arg-dependent) [25, 26] but does not mount a continuous infection in
normal tissues. It receives sufficient nutritional support from tumor tissue. S. typhi-
murium A1-R replicates in tumor tissues by more than 1,000-fold compared with
normal tissues [26]. S. typhimurium A1-R has only auxotrophic mutations for leu
and arg, and is therefore not over-attenuated. Further, S. typhimurium A1-R was
selected for increased virulency by in vivo tumor passage [25]. Previously, we re-
ported that tumor-targeting S. typhimurium A1-R was effective against many types
of PDOX models including melanoma [25, 27, 28, 29], sarcoma [30, 31, 32, 33, 34]
and pancreatic cancer [35, 36].
In this manuscript, we evaluated the efficacy of S. typhimurium A1-R against the
imatinib-resistant GIST PDOX model [37].2. Materials and methods
2.1. Animals
In the present study, 4e6 weeks old, athymic nu/nu male nude mice (AntiCancer,
Inc., San Diego, CA), were utilized. All experimental protocols and data were
collected as previously described [27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37]. All
mice were housed in a barrier facility on a high efficiency particulate arrestance
(HEPA)-filtered rack under standard 12-hour light-dark cycles conditions. Mice
were fed an autoclaved laboratory rodent diet. Anesthesia and analgesics wereon.2018.e00643
vier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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mg/kg ketamine, 15.2 mg/kg xylazine, and 0.48 mg/kg acepromazine maleate)
was utilized subcutaneously for all mice. The animals were observed carefully dur-
ing surgery to maintain adequate depth of anesthesia. The animals were monitored
daily and humanely sacrificed by CO2 inhalation when they met the following
criteria: severe tumor burden (more than 20 mm in diameter), prostration, significant
body weight loss, difficulty breathing, rotational motion, and body temperature drop.2.2. Establishment of the GIST PDOX model
The patient received primary surgery in the Department of Surgery, University of
California, Los Angeles (UCLA). All experimental protocol and data collection
were as described [27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37]. The patient recurred
and received imatinib as neoadjuvant chemotherapy to make the tumor easier to
resect and to reduce the chances of rupture. Curative surgery for recurrence was per-
formed and resected fresh tumor was brought to AntiCancer Inc. from the UCLA
Hospital. The tumor has mutations in c-kit in exons 11 and 17. The GIST tumor
was initially established subcutaneously in nude mice. Surgical orthotopic implanta-
tion to the anterior gastric wall of nude mice was subsequently performed to estab-
lish the GIST PDOX model using tumor tissue previously grown subcutaneously
(Fig. 1-A). Laparotomy was performed to measure the established tumor size
when the tumor was palpable over the skin (Fig. 1-B). All experimental protocols
provided in this manuscript are based on our previous publications [27, 28, 29,
30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40].Fig. 1. Surgical orthotopic implantation (SOI). A: The stomach of a nude mouse under ketamine anes-
thesia was gently exteriorized through an abdominal incision and a small GIST fragment was implanted
on the anterior gastric wall after slight tearing of the serosa (white arrow). Scale bar: 10 mm. B: The
GIST PDOX model was observed after 6 weeks. The area surrounded by black broken lines indicates
the established tumor.
on.2018.e00643
vier Ltd. This is an open access article under the CC BY license
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All experimental protocols and data were collected as previously described [27, 28,
29, 30, 31, 32, 33, 34, 35, 36, 37]. Green fluorescent protein (GFP)-expressing
S. typhimurium A1-R bacteria (AntiCancer Inc.,) were grown in LB medium (Fisher
Sci., Hanover Park, IL, USA) and then diluted 1:10 in LB medium. Bacteria were
harvested at late-log phase, washed twice with PBS, then diluted in phosphate-
buffered saline (PBS) to 5  108 colony-forming units (CFU)/ml. S. typhimurium
A1-R (5  107 CFU) in 100 ml PBS was injected i.v. in each mouse [38].2.4. Treatment protocol for the GIST PDOX model
All experimental protocols and data were collected as previously described [27, 28,
29, 30, 31, 32, 33, 34, 35, 36, 37]. The PDOXmodels were randomized into 3 groups
described below when tumor volume reached 60 mm3; G1: untreated group; G2: im-
atinib (50 mg/kg, oral administration [p.o.], daily, 3 weeks); G3: S. typhimurium
A1-R (5  107 CFU/body, i.v., weekly, 3 weeks) (Fig. 2). Dosages of imatinib
and S. typhimurium A1-R were determined from published reports [32, 37]. Tumor
volume was evaluated on day 0 and day 22 by laparotomy with the following for-
mula: tumor volume (mm3) ¼ length (mm)  width (mm)  width (mm)  1/2.
Body weight was measured twice a week. All mice were sacrificed on day 22.2.5. Imaging of S. typhimurium A1-R
The FV1000 confocal microscope (Olympus, Tokyo, Japan) was used to visualize S.
typhimurium A1-R-GFP in the GIST PDOX tumor by GFP fluorescence. Fluores-
cence images were obtained with the 20/0.50 UPlan FLN and 40/1.3 oil
Olympus UPLAN FLN objectives [39].No treatment
Imatinib
Day 1 Day 8 Day 21
G1: nontreated group 
(n=6)
G2: Imatinib group 
(n=6, PO, daily)
Day 15 
G3: S. typhimurium A1-R group 
(n=6, i.v., weekly)
Day 22
Sacrifice
Day 0
Laparotomy
S. typhimurium A1-R S. typhimurium A1-R S. typhimurium A1-R
Fig. 2. Treatment protocol. G1: untreated group; G2: imatinib (50 mg/kg, oral administration [p.o.],
daily, 3 weeks); G3: S. typhimurium A1-R (100 CFU/body, i.v., weekly, 3 weeks). Each group consisted
of 6 mice. All mice were sacrificed on day 22.
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Article Nowe006432.6. Histological examination
10% formalin fixed, paraffin-embedded tissue sections (5 mm) were deparaffinized in
xylene and rehydrated in an ethanol series. Hematoxylin and eosin (H&E) staining
was done according to standard protocols. Histological examination was observed
with a BHS system microscope (Olympus Corp., Tokyo, Japan).2.7. Statistical analysis
All statistical analyses were performed with the Statistical Package for the Social
Sciences for Windows software version 22.0 (IBM Corp., Armonk, NY, USA). Sig-
nificant differences for comparisons of intragroup were determined using one-way
ANOVA followed by Tukey post hoc pairwise tests. Bar graphs show mean values
and error bars express  standard deviation. A probability value of P < 0.05 was
considered as statistical significant.2.8. Ethical considerations
All animal experiments were done at AntiCancer Inc. with an Institutional Animal
Care and Use Committee (IACUC)-protocol solely approved for present study
and following the principles and procedures defined in the National Institutes of
Health (NIH) Guide for the Care and Use of Animals under Assurance Number
A3873-1. Informed consent was obtained from the patient, and this study was
approved by the Institutional Review Board of UCLA (IRB #10-001857).3. Results
3.1. Efficacy of S. typhimurium A1-R and imatinib on the GIST
PDOX tumor growth
Imatinib is first line treatment for GIST. Secondary mutations in c-kit have been
shown to be the prime cause of resistance to imatinib in GIST. A few studies
have demonstrated that GIST patients respond better to imatinib if their tumors
contain c-kit mutations in exon 11 compared to exon 9 [5, 41, 42, 43]. Despite
the clinical success of imatinib, several studies have attributed the development
of acquired resistance of GIST to imatinib. In addition, second and third-
generation c-KIT inhibitors were not able to completely overcome imatinib resis-
tance in GIST. Therefore, a better treatment option is urgently needed. To
address this issue, we tested the efficacy of tumor-targeting S. typhimurium
A1-R compared to imatinib on the GIST PDOX. We established the GIST
PDOX model using surgical orthotopic implantation in the anterior gastric
wall (Fig. 1). The schematic treatment design is shown in Fig. 2. Three weeks
after S. typhimurium A1-R injection, tumor volumes in each group wereon.2018.e00643
vier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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We found that S. typhimurium A1-R reduced the GIST PDOX tumor growth
significantly in contrast to the untreated group (P ¼ 0.001). The efficacy of S.
typhimurium A1-R was much greater than imatinib (P ¼ 0.013). However, im-
atinib treatment did not show significant efficacy in contrast to the untreated
group (P ¼ 0.462). The final tumor volume ratios (day 22/day 0) were as fol-
lows: untreated group (G1) (4.96  1.37); imatinib group (G2) (4.17  0.69);
S. typhimurium A1-R group (G3) (2.01  0.93).3.2. Effect of imatinib and S. typhimurium A1-R treatment on
body weight
The body weight of the GIST PDOX mice was measured pre-treatment and post-
treatment either with imatinib or S. typhimurium A1-R. We did not find any signif-
icant difference in body weight between the three groups (Fig. 4).3.3. Imaging of tumor-targeting S. typhimurium A1-R in the
GIST PDOX
After intravenous (i.v.) administration of S. typhimurium A1-R for three weeks, the
accumulation of the GFP-expressing S. typhimurium A1-R in the GIST PDOX tu-
mor was observed using confocal microscopy (Fig. 5).P = 0.462
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Fig. 3. Tumor volume ratio. Bar graphs show the tumor volume ratio (post-treatment volume/pre-
treatment volume). S. typhimurium A1-R suppressed tumor growth significantly compared to the un-
treated group (P ¼ 0.001). There was also a significant difference between the S. typhimurium A1-R
group and the imatinib group (P ¼ 0.013). Imatinib did not show significant efficacy compared to the
untreated control (P ¼ 0.462). N ¼ 6 mice/group. Error bars: SD.
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Fig. 4. Body weight of each group. Bar graphs show pre-treatment and post-treatment body weight of
the GIST PDOX mice treated with each drug. There was no significant difference between any group.
N ¼ 6 mice/group. Error bars: SD.
Fig. 5. Fluorescence imaging of S. typhimurium A1-R-GFP targeting the GIST PDOX model. Broken
black lines indicate tumor treated with S. typhimurium A1-R which was visualized by confocal imaging
with the FV1000 (Olympus, Tokyo, Japan). Left scale bar: 10 mm; Right scale bar: 20 mm.
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Laparotomy images at post-treatment on day 22 (Fig. 6AeC) showed that S. typhi-
muriumA1-R-treated mice had reduced tumor volume (Fig. 6C) compared to control
(Fig. 6A) and imatinib (Fig. 6B) groups. High-power photomicrographs of tumor
sections are provided with hematoxylin and eosin (H&E) staining. H&E staining
of paraffin-embedded tumor sections did not contain necrotic areas in the controlon.2018.e00643
vier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
Fig. 6. Representative laparotomy images of each group on day 22 (AeC). The area surrounded by the
black line indicates tumor. A. Control group. B. Imatinib group. C. S. typhimurium A1-R group. Scale
bars: 10 mm. Histology (DeF). D. Hematoxylin and eosin (H&E) staining of the untreated PDOX tumor.
E. H&E staining of the imatinib-treated PDOX tumor. F. H&E staining of the S. typhimurium A1-R-
treated PDOX tumor. Necrosis was observed (white arrows). Scale bars: 200 mm.
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extensive necrosis (Fig. 6C).4. Discussion
Our present study demonstrates the power of the PDOX model to establish novel
efficacious therapy for resistant cancer. To fulfill the goal of precision personalized
oncology, our laboratory established the PDOX nude mouse model using the tech-
nique of surgical orthotopic implantation (SOI), including pancreatic [40, 41, 42, 43,
44, 45], breast [46], ovarian [47], lung [48], cervical [49], colon [50, 51, 52], and
stomach cancer [53], sarcoma [34, 35, 54, 55, 56, 57, 58, 59, 60, 61], and melanoma
[30, 31, 32, 62, 63].
Accumulative evidence suggests the effectiveness of imatinib in both the adjuvant
and metastatic GISTs in patients with KIT or PDGFRA mutations [64, 65, 66,
67]. However, imatinib was not effective in all patients, because it was found that
GIST patients with mutations in the exon 9 of the KIT gene have lower effectiveness
compared to mutations in exon 11 [41, 67, 68].
Since exon-11-mutant KIT GIST is heterogeneous, it was advisable to plan treat-
ment strategies based on individual mutant cohorts [68]. Imatinib can improve the
prognosis of advanced GIST patients [68, 69]. However, almost all such cases
become resistant to these drugs due to secondary mutations in c-kit or PDGFRa
[68, 69]. The present case also had a secondary mutation in exon 17 and failedon.2018.e00643
vier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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effective therapy for TKI-resistant GIST remains a major challenge.
S. typhimurium A1-R may be a general therapeutic for cancer. S. typhimurium A1-R
is auxotrophic for leuearg, which prevents it from mounting a continuous infection
in normal tissues. S. typhimurium A1-R inhibited or eradicated primary and metasta-
tic tumors as monotherapy in nude-mouse models of major cancers [70, 71],
including prostate [72], breast [38, 46, 73, 74], lung [75], pancreatic [36, 37, 76,
77, 78], ovarian [79, 80], stomach [81], and cervical cancer [82], glioma [83, 84],
as well as sarcoma [35, 54], including osteosarcoma [85, 86], all of which are highly
aggressive tumor models. Several different types of bacteria such as Salmonella, Lis-
teria, Escherichia, and Clostridium have been reported to either target or destroy
solid tumors. Among these bacteria, several strains of Salmonella even colonize
solid tumors and display antitumor immunity [87]. Thus, tumor-targeting bacteria
have great potential in curing solid tumors [88, 89, 90, 91, 92, 93, 94].
In the present case, S. typhimuriumA1-Rwas effective in theGISTPDOXmodelwith a
secondary mutation in exon 17, suggesting that S. typhimurium A1-R be developed
clinically for TKI-resistant GIST patients. S. typhimuriumA1-R showed significant ef-
ficacy in an imatinib-resistantGISTPDOXmodelwith secondarymutations in the c-kit
gene. S. typhimuriumA1-R decoys quiescent tumor cells fromG0/G1 to S/G2/M phase,
which makes cancer cells sensitive to chemotherapy [82]. We previously reported that
S. typhimurium A1-R in this way overcomes the resistance to chemotherapy [30, 34].
Thus, the combination of S. typhimuriumA1-R and imatinib to overcome the resistance
to imatinib is warranted going forward. Further, S. typhimuriumA1-R efficacy on other
subtypes of GIST in PDOX models should be investigated in the future.
Future experiments are needed to understand the molecular mechanism by which
S. typhimurium A1-R could overcome the imatinib-resistant GIST PDOX model.
This would be crucial for designing effective treatment regimens. Kim et al. [94] re-
ported that tumor colonization by S. typhimurium defective in ppGpp synthesis
(DppGpp Salmonellae) resulted in a significant increase in the level of interleukin
(IL)-1b and tumor necrosis factor-a (TNF-a) within the tumor mass, specifically
during the tumor-suppression stage. Their results suggest that IL-1b and TNF-a
play crucial roles in Salmonella-mediated cancer therapy. We also found accumula-
tion of S. typhimurium A1-R within the tumor site and increased necrosis in
our GIST PDOX. It is also reported that systematic injection of IL2-expressing
S. typhimurium reduced angiogenesis and increased necrosis within tumor tissues
[95]. We believe that one of above these mechanisms may be effective in our model
system. Long-term followup and more patient data will be needed to further validate
our findings.
Zhao et al. [71] reported that S. typhimuriumA1-R directly targets and kills cancer cells.
The present study reflects this property. It is known that bacteria usually can beon.2018.e00643
vier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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tumor necrosis high concentrations of nutrients such as purines [96] and lack of immu-
nologic surveillance promote the growth and survival of bacteria at the tumor site [96].
Li et al. [97] using immune-deficient nude mice reported that S. typhimurium strain
SL7207 was enriched in the tumor and inhibited tumor growth. These results suggest
that systemic S. typhimuriummay be eliminated bymechanisms other than the immune
system. Using nude-mouse models which are T-cell deficient, it has been shown that
S. typhimurium A1-R destroys tumor blood vessels [76]. In addition, an increase in
TNF-a in blood and a high influx of blood into tumors by vascular disruption resulted
in influx of bacteria into the tumor together with the blood [98]. Since these and our
studies used immunodeficient mice, it will be crucial to test the anticancer efficacy of
S. typhimurium A1-R in an immunocompetent mice. Recently Zhang et al. [99] tested
the toxicologic and biodistribution of tumor-targeting S. typhimurium A1-R and
S. typhimuriumVNP20009 in a syngeneic tumor model growing in immunocompetent
BALB/c mice. They found a safe dose and schedule of S. typhimurium A1-R adminis-
tration in BALB/c mice that is efficacious against tumor growth. They found greater
antitumor efficacy of S. typhimurium A1-R in an immunocompetent mouse model
[99]. These results together with present data suggest that S. typhimurium A1-R could
be a therapeutic option for imatinib-resistant GIST.Declarations
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